Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Challenges and outcome of surgery for bowel obstruction in women with gynaecologic cancer.

Furnes B, Svensen R, Helland H, Ovrebo K.

Int J Surg. 2016 Mar;27:158-64. doi: 10.1016/j.ijsu.2016.02.002.

PMID:
26853847
2.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators..

Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8.

3.

Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.

Trovik J, Wik E, Werner HM, Krakstad C, Helland H, Vandenput I, Njolstad TS, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC; MoMaTEC study group., Amant F, Akslen LA, Salvesen HB.

Eur J Cancer. 2013 Nov;49(16):3431-41. doi: 10.1016/j.ejca.2013.06.016.

4.

Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas.

Haldorsen IS, Berg A, Werner HM, Magnussen IJ, Helland H, Salvesen OO, Trovik J, Salvesen HB.

Gynecol Oncol. 2012 Sep;126(3):413-8. doi: 10.1016/j.ygyno.2012.05.009.

PMID:
22609110
5.

Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists.

Haldorsen IS, Husby JA, Werner HM, Magnussen IJ, Rørvik J, Helland H, Trovik J, Salvesen ØO, Espeland A, Salvesen HB.

Eur Radiol. 2012 Jul;22(7):1601-11. doi: 10.1007/s00330-012-2400-y.

PMID:
22453859
6.

Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective.

Trovik J, Mauland KK, Werner HM, Wik E, Helland H, Salvesen HB.

Gynecol Oncol. 2012 May;125(2):381-7. doi: 10.1016/j.ygyno.2012.01.050.

PMID:
22307064
7.

A phase 3 trial of bevacizumab in ovarian cancer.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators..

N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284.

8.

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S.

Ann Oncol. 2012 May;23(5):1185-9. doi: 10.1093/annonc/mdr441.

PMID:
21976386
9.

Genome-wide association study identifies a common variant associated with risk of endometrial cancer.

Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O'Mara T, Walker LC, Montgomery SB, Dermitzakis ET; Australian National Endometrial Cancer Study Group., Fahey P, Montgomery GW, Webb PM, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Coenegrachts L, Vergote I, Amant F, Salvesen HB, Trovik J, Njolstad TS, Helland H, Scott RJ, Ashton K, Proietto T, Otton G; National Study of Endometrial Cancer Genetics Group., Tomlinson I, Gorman M, Howarth K, Hodgson S, Garcia-Closas M, Wentzensen N, Yang H, Chanock S, Hall P, Czene K, Liu J, Li J, Shu XO, Zheng W, Long J, Xiang YB, Shah M, Morrison J, Michailidou K, Pharoah PD, Dunning AM, Easton DF.

Nat Genet. 2011 May;43(5):451-4. doi: 10.1038/ng.812.

10.

[Medical abortion--the first Norwegian experiences].

Iversen OE, Midbøe G, Johnsen SL, Augestad G, Økland I, Helland H, Strray-Pedersen S, Bjørge L.

Tidsskr Nor Laegeforen. 2003 Sep 11;123(17):2422-4. Norwegian.

11.

Early pregnancy termination with mifepristone and misoprostol in Norway.

Bjørge L, Johnsen SL, Midbøe G, Augestad G, Økland I, Helland H, Stray-Pedersen S, Iversen OE.

Acta Obstet Gynecol Scand. 2001 Nov;80(11):1056-61.

PMID:
11703208
12.

The general health in women suffering from gynaecological disorders is improved by means of hysterectomy.

Rannestad T, Eikeland OJ, Helland H, Qvarnström U.

Scand J Caring Sci. 2001;15(3):264-70.

PMID:
11564235
13.

Are the physiologically and psychosocially based symptoms in women suffering from gynecological disorders alleviated by means of hysterectomy?

Rannestad T, Eikeland OJ, Helland H, Qvarnström U.

J Womens Health Gend Based Med. 2001 Jul-Aug;10(6):579-87.

PMID:
11559455
14.
15.

Quality of life, pain, and psychological well-being in women suffering from gynecological disorders.

Rannestad T, Eikeland OJ, Helland H, Qvarnström U.

J Womens Health Gend Based Med. 2000 Oct;9(8):897-903.

PMID:
11074956

Supplemental Content

Loading ...
Support Center